Mediterranean-style diets found to cut heart risks

Pour on the olive oil, preferably over fish and vegetables: One of the longest and most scientific tests of a Mediterranean diet suggests this style of eating can cut the chance of suffering heart-related problems, especially strokes, in older people at high risk of them.

The study lasted five years and involved about 7,500 people in Spain. Those who ate Mediterranean-style with lots of olive oil or nuts had a 30 percent lower risk of major cardiovascular problems compared to those who were told to follow a low-fat diet but who in reality, didn't cut fat very much. Mediterranean meant lots of fruit, fish, chicken, beans, tomato sauce, salads, and wine and little baked goods and pastries.

Mediterranean diets have long been touted as heart-healthy, but that's based on observational studies that can't prove the point. The new research is much stronger because people were assigned diets to follow for a long time and carefully monitored. Doctors even did lab tests to verify that the Mediterranean diet folks were consuming more olive oil or nuts as recommended.

Most of these people were taking medicines for high cholesterol and blood pressure, and researchers did not alter those proven treatments, said one study leader, Dr. Ramon Estruch of Hospital Clinic in Barcelona.

But as a first step to prevent heart problems, "we think diet is better than a drug" because it has few if any side effects, Estruch said. "Diet works."

Results were published online Monday by the New England Journal of Medicine and were discussed at a nutrition conference in Loma Linda, Calif.

People in the study were not given rigid menus or calorie goals because weight loss was not the aim. That could be why they found the "diets" easy to stick with — only about 7 percent dropped out within two years. There were twice as many dropouts in the low-fat group than among those eating Mediterranean-style.

Researchers also provided the nuts and olive oil, so it didn't cost participants anything to use these relatively pricey ingredients. The type of oil may have mattered — they used extra-virgin olive oil, which is minimally processed and richer than regular or light olive oil in the chemicals and nutrients that earlier studies have suggested are beneficial.

The study involved people ages 55 to 80, just over half of them women. All were free of heart disease at the start but were at high risk for it because of health problems — half had diabetes and most were overweight and had high cholesterol and blood pressure.

They were assigned to one of three groups: Two followed a Mediterranean diet supplemented with either extra-virgin olive oil (4 tablespoons a day) or with walnuts, hazelnuts and almonds (a fistful a day). The third group was urged to eat a low-fat diet heavy on bread, potatoes, pasta, rice, fruits, vegetables and fish and light on baked goods, nuts, oils and red meat.

Independent monitors stopped the study after nearly five years when they saw fewer problems in the two groups on Mediterranean diets.

Doctors tracked a composite of heart attacks, strokes or heart-related deaths. There were 96 of these in the Mediterranean-olive oil group, 83 in the Mediterranean-nut group and 109 in the low-fat group.

Looked at individually, stroke was the only problem where type of diet made a big difference. Diet had no effect on death rates overall.

The Mediterranean diet proved better even though its followers ate about 200 calories more per day than the low-fat group did. The study leaders now are analyzing how each of the diets affected weight gain or loss and body mass index.

The Spanish government's health research agency initiated and paid for the study, and foods were supplied by olive oil and nut producers in Spain and the California Walnut Commission. Many of the authors have extensive financial ties to food, wine and other industry groups but said the sponsors had no role in designing the study or analyzing and reporting its results.

Rachel Johnson, a University of Vermont professor who heads the American Heart Association's nutrition committee, said the study is very strong because of the lab tests to verify oil and nut consumption and because researchers tracked actual heart attacks, strokes and deaths — not just changes in risk factors such as high cholesterol.

"At the end of the day, what we care about is whether or not disease develops," she said. "It's an important study."

Rena Wing, a weight-loss expert at Brown University, noted that researchers provided the oil and nuts, and said "it's not clear if people could get the same results from self-designed Mediterranean diets" — or if Americans would stick to them more than Europeans who are used to such foods.

Dr. George Bray of the Pennington Biomedical Research Center in Baton Rouge, La., said he would give the study "a positive — even glowing — comment" and called it "the best and certainly one of the largest prospective dietary trials ever done."

"The data are sufficiently strong to convince me to move my dietary pattern closer to the Mediterranean Diet that they outline," he added.

Another independent expert also praised the study as evidence diet can lower heart risks.

"The risk reduction is close to that achieved with statins," cholesterol-lowering drugs, said Dr. Robert Eckel, a diet and heart disease expert at the University of Colorado.

"But this study was not carried out or intended to compare diet to statins or blood pressure medicines," he warned. "I don't think people should think now they can quit taking their medicines."

___

Online:

Journal: http://www.nejm.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Read More..

Lens Blog: The Largely Unknown Photography of Lola Álvarez Bravo

The year 2007 was a pretty good one for rediscovering long-forgotten images in Mexico. Most people already know about Robert Capa’s Mexican suitcase, a trove of his work from the Spanish Civil War. But that same year an unknown archive of vintage prints by Mexico’s greatest photographers was also discovered, left behind in the longtime home of Lola Álvarez Bravo.

The find, known as the Gonzalez-Rendon archive, had prints and original photomontages by Lola, as well as some beautifully printed images by Manuel Álvarez Bravo, to whom she had been married for several years. The find also included work by some of Lola’s students who had gone on to become noted photographers, Mariana Yampolsky and Raul Conde, among them.

Though overshadowed by her more famous partner, who had resisted her foray into photography, Lola ranks among Mexico’s most celebrated photographers, having done portraits of fellow artists and intellectuals as well as work among the indigenous and poor, whom she portrayed with a sense of compassion and social criticism. Her images provide a window in what she — a working photographer and teacher most of her life — valued as an artistic statement.

“It’s what an art historian dreams about, finding the missing pieces,” said James Oles, a lecturer at Wellesley College who was among the first to inspect the images in Mexico. “The material fleshes out some aspects of her work, giving us original titles and dates that radically change the meaning and interpretation of a work of art. And the original photomontages give an idea how she created them.”

Born Dolores Concepcion Martinez in 1903, she grew up in a wealthy family, although she had to move in with relatives when her father died. She first met Manuel in her youth, marrying him in 1925. As an accountant, he was sent to work in Oaxaca, where the couple began to take pictures, Mr. Oles wrote in his recently published book, “Lola Álvarez Bravo and the Photography of an Era.”

The area’s poverty struck her, and it elicited a compassion in her work that was different from her husband’s more complex images.

“Lola was maybe a little more natural,” Mr. Oles said. “She was interested in more candid and less intrusive images. She was certainly more interested in people than things.”

The couple separated in 1934, divorcing in 1949. Throughout, she kept his name and did not remarry. She supported herself as a photographer working for government agencies, as well as teaching, where she influenced many.

“I think Lola was a remarkable photographer, especially given all the challenges she faced,” said Elizabeth Ferrer, who published “Lola Álvarez Bravo” with Aperture. “There were women artists, though women were not supposed to be working in the street but in the studio. But the kind of photography done at the time involved a greater public interface, and the fact that she did that showed her incredible strength and desire to photograph the world around her.”

Although she found her own path apart from her more famous husband — she was more gregarious, enjoying the company of artists, writers and intellectuals — work and circumstance worked against her. It was not until the 1980s, Mr. Oles said, that her work as an artist came to the fore.

Mr. Oles visited her in the early 1990s, around the time when the Center for Creative Photography at the University of Arizona acquired an archive of her work. Lola was moved by her son to another apartment, and she died in 1993.

Fourteen years later, Mr. Oles got a call from a museum in Mexico City. Relatives of one of Lola’s friends, who had purchased her old apartment, had been safeguarding several boxes that had been left behind. One of them had taken the time to preserve and order the prints.

“She didn’t sell anything or have it framed in her apartment, but just organized it,” Mr. Oles said. “When I went there, it was amazing. It showed what had been separated at some time by Lola, and God knows when or why, there were a lot of her own photos. Many were by students of hers as well as a group of extraordinary vintage photos by Manuel Álvarez Bravo.”

Her photos — including some vintage prints that were exhibited in Philadelphia in 1943 — shed new light on her work. In some cases, original titles gave new meaning to old images. One shot of an indigenous woman seated against a wrought-iron fence that had long been titled “By the Fault of Others” turned out to have “Death Penalty” (Slide 6) as its original title.

“That changes how we interpret this photo of this woman who looks trapped by this grille,” Mr. Oles said. “You can go into the archive of any major photographer and find images they never printed and exhibit them after their death without knowing what they mean. Finding this material tells us these are the photos she chose which she thought were the key images that she was interested in during that era.”

While her photomontages are well known, the archive has the originals, which she made by gluing together cut-out images she would later photograph for the final montage.

“In Mexico, photomontage was mainly a strategy of media and advertising, not an artistic project,” Mr. Oles said. “What Lola was trying to do was elevate it to the realm of high art and view it as equivalent to muralism. The multiple perspectives of photomontage and the fragmented images resolved into a whole are what a muralist like Diego Rivera does when he shows multiple perspectives of a factory and resolving them together. Lola understood that.”

Among the greatest finds in the archive are works by her students. Even in death, though, Lola’s own images prove to affect a current generation. Mr. Oles said her photos of prostitutes, titled “Triptych of the Martyrs,” has a powerful element of feminist criticism.

“Their faces are obscured with wound-like shadows,” he said. “There is this undercurrent of social critique. Whenever my students see those pictures, they are moved sometimes to the point of tears. I don’t think any of Manuel Álvarez Bravos’s photos move them to tears.”

---

The exhibit “Lola Álvarez Bravo and the Photography of an Era” will be on view at the Center for Creative Photography in Tucson from March 30 through June 23.

Follow @dgbxny and @nytimesphoto on Twitter. Lens is also on Facebook.

Read More..

Live Twitter surgeries hit with hospitals, public

HOUSTON (AP) — Amy Shireman logged into Twitter early Wednesday to join thousands of people from 60 countries watch live something she had experienced but never seen: a baby boy delivered by cesarean section, in all its graphic imagery.

The live Twitter broadcast brought to viewers by Houston’s Memorial Hermann Health System was the medical institution’s latest foray into a growing trend to gain exposure by showing the world via social media routine procedures that happen daily in operating rooms.

While the Internet and social media have been a part of the medical industry for years, hospitals and doctors are now using it to gain leverage in a competitive market. And what better way to do that than provide people with an authentic online version of the kinds of surgeries they’ve been watching for years on fictional TV shows such as “Grey’s Anatomy,” ”House” and “ER?”

“It’s fascinating to pull back the curtain on the mystery of the OR,” said Natalie Camarata, the social media manager at Houston’s Memorial Hermann Hospital who helped broadcast Wednesday’s C-section as well as two other procedures, including a brain surgery done by Dr. Dong Kim, who gained notoriety when he treated former U.S. Rep. Gabrielle Giffords after she was shot in the head in 2011.

Through a variety of matrices that help track online activity, Camarata estimated that 72,000 watched the C-section live on Twitter, while an additional 11,000 viewed it in another format. The viewers were from 60 countries, she said, with the most international followers coming from Germany, Norway and Israel.

During the procedure, viewers tweeted questions, and doctors or staff responded. One viewer from Norway asked about the difference in how the umbilical cord is treated in a C-section. Several tweeted congratulations. In the two hours the hospital was live, it gained more than 600 followers, dozens of them in the first few minutes. Several noted the images were gory, joking they wouldn’t watch it over breakfast.

Shireman, a 35-year-old mother of two from Pittsburgh, was intrigued to see “what was happening beyond the curtain” after having two C-sections herself. While she had hoped the hospital would focus more on the risks, she said she would watch it again, and would consider watching other surgeries.

“The pictures of watching that baby come out of the womb were just amazing” Shireman said. “I know it was delayed a bit … but it did have that live feel like you were right there in the OR.”

Previously, when Memorial Hermann live tweeted a brain surgery, more than 235,000 watched, more than 280,000 viewed photos and video and the hospital gained 7,000 new followers. With each event, the hospital finds more and different people participating, Camarata said.

“When hospitals did it several years back, the online audience wasn’t fully engaged,” she said. “Now people are living Twitter, living Facebook. It’s part of their everyday life.”

Tyler Haney, the vice president of digital marketing at the University of Pittsburgh Medical Center, said his hospital system has not live tweeted a surgery but also has not ruled it out. For now, it is focusing on innovative things at the center, like providing the online audience an opportunity to interact with a brain computer interface, which increased traffic from social media outlets by 120 percent.

This trend — which the medical industry latched on to later than others — will only grow, he said, quoting statistics that found 57 percent of people saying a social media connection would have a “strong impact” on their decision to seek treatment at a given hospital.

The Mayo Clinic has been a leader in the field, said Lee Aase, the clinic’s social media director but has opted not to do live events from the OR, feeling that it is voyeuristic and does not provide additional benefits. The clinic has focused instead on question-and-answer sessions on specific topics.

“People are taking their social network connections with them wherever they go and we certainly are seeing building interest in this,” he said.

Dr. Anne Gonzalez, one of the surgeons who participated in the C-section and is affiliated with the system’s women’s hospital, said social media helps doctors navigate a competitive market.

“There’s a lot of challenges with trying to make patients understand what you think is best for them in a very non-paternalistic way, and I think Twitter helps with that,” she said.

Swedish Health Services, which has five hospitals and more than 100 clinics in the Seattle area, recently live tweeted an ear surgery, said Dana Lewis, manager of digital marketing and internal communications, using only words and photos to reach a hearing-impaired audience.

The hospital also live tweeted a patient going through a sleep clinic and had some 10,000 people follow it in the middle of the night, she said.

“It’s about reaching people where they are, so it doesn’t make sense to have a seminar in the afternoon about not being able to sleep. Why not do it in the middle of the night … when they can’t sleep and they want to find out more about how they can get help?” Lewis said. “That’s the beauty of social media.”

___

Plushnick-Masti can be followed on Twitter at https://twitter.com/RamitMastiAP

Social Media News Headlines – Yahoo! News

Title Post: Live Twitter surgeries hit with hospitals, public
Url Post: http://www.news.fluser.com/live-twitter-surgeries-hit-with-hospitals-public/
Link To Post : Live Twitter surgeries hit with hospitals, public
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Predict the Oscar Winners!

• Facebook


• Tweet

• Facebook


• Tweet

Cast your vote for who will be the night's big winners Click here to download a printable ballot.

Click here to download a printable ballot.

Polls
completed:

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..

Letter From Washington: A Struggle for Control of Republican Party

WASHINGTON — The late William F. Buckley and Karl Rove have little in common, other than the Republican Party and intelligence. Mr. Buckley’s politics were guided by principles; Mr. Rove’s principles are guided by politics.

Yet Mr. Rove, the party establishment’s money and strategy guru, is channeling Mr. Buckley, a founding father of contemporary conservatism, by trying to root out extremism from the Republican mainstream. A half-century ago, Mr. Buckley sought to expunge the John Birch Society, anti-Semites and white supremacists from the party’s inner circles. Today, Mr. Rove is threatening to finance primary campaigns against those he considers right-wing extremists of the type that have already cost Republicans several Senate seats.

It may be the right purpose, but he’s the wrong person. He can’t avoid looking like an inside-the-Beltway kingmaker trying to purge populist insurgencies around the country and make some more bucks while doing it. There is a backlash.

Still, prominent Republicans with more credibility than Mr. Rove need to consider this cause. There are more than a few fringe figures who play a role in defining the party, many of them express a vitriolic dislike of President Barack Obama that turns off possible Republican voters.

There is Representative Steve King of Iowa, who is unrelenting in his criticism of the president. One of his latest targets is the September attack in Benghazi, Libya, in which four Americans, including the U.S. ambassador, were killed.

He goes further than other critics: Benghazi, he declares, “is a lot bigger” than other scandals. It is, he says, at least 10 times bigger than Watergate and Iran-contra combined.

Mr. King has made a name for himself with anti-immigrant rants. Last year, he said Americans should select eligible immigrants the same way they would go about picking a “good bird dog.” That means choosing “the one that’s the friskiest, the one that’s engaged the most, and not the one that’s over there sleeping in the corner.” He later explained that he meant this as a compliment — he likes bird dogs.

Then there’s Representative Paul C. Broun of Georgia. The former physician said evolution, embryology and the Big Bang theory are “lies straight from the pit of hell.” He once proposed banning Playboy magazine from military installations, which might have jeopardized the survival of the all-volunteer army.

Like more than a few of his colleagues on the right, he directs his greatest vitriol at Mr. Obama. Mr. Broun boasts that he was the first to call the president “a socialist who embraces Marxist-Leninist policies.” The “only Constitution that Barack Obama upholds is the Soviet constitution,” he charges.

These two lawmakers aren’t simply innocuous backbenchers. They are among the leading contenders in Republican primaries for open Senate seats in Georgia and Iowa.

Even some Republicans who aren’t as far out get caught up in the fervor, particularly when it touches on Mr. Obama. This month, Representative Virginia Foxx of North Carolina likened those who didn’t fight hard enough against the Obama administration’s regulation of for-profit colleges to Germans who didn’t stand up to the Nazis in the 1930s.

Texas, the biggest Republican-dominated state, is a hotbed of Obama-hating politicians. Louie Gohmert, in his fifth term in the U.S. House of Representatives, asserted in November that the president ousted the dictator Col. Muammar el-Qaddafi to allow Al Qaeda to take over Libya.

After a 15-year hiatus, Steve Stockman returned to the House this year and wasted no time. When the president appeared at a news conference surrounded by children after the school shooting in Newtown, Connecticut, Mr. Stockman compared Mr. Obama to Saddam Hussein for using children as props. He’s now talking about impeaching Mr. Obama for proposing gun-control legislation.

The Senate is hardly immune. Senator Ted Cruz of Texas, who was elected in November, questioned, with no cause, whether Chuck Hagel, the defense secretary nominee, had taken money from terrorist states. The comment was criticized even by the Republican senator John McCain, himself a Hagel critic. Far from expressing regret, Mr. Cruz seemed to revel in the controversy.

This transcends ideology. Mr. Broun has the least conservative voting record of any House Republican from Georgia, according to the latest National Journal survey of voting records. Claiming the president worships the constitution of the Soviet Union isn’t a conservative position — it’s a nutty one, reminiscent of the John Birchers that Mr. Buckley assailed a half-century ago.

Another new senator, Jeff Flake of Arizona, is every bit as conservative as Mr. Cruz, and they will probably vote alike most of the time. Yet Mr. Cruz revels in vilification, while Mr. Flake seeks common ground when possible.

It is the Flake persona that should offer the greatest appeal to younger or more independent voters. Many conservatives insist that the United States is a center-right country, where voters are receptive to the case for limited government and cultural traditionalism. The changing demographic profile of the electorate seems to undercut that case.

That is a good debate to have. But conservatives can’t compete in the argument when their party is identified with bizarre theories, bigotry and a visceral hatred of the president.

That’s going to change when prominent Republicans with conservative bona fides — Representative Paul D. Ryan of Wisconsin, Senator Marco Rubio of Florida — don’t just talk the talk about a broader-based party but walk the walk and reject the haters.

Read More..

Mandiant goes viral after China hacking report

(Reuters) – Cybersecurity company Mandiant Corp won plaudits from its peers and made front-page news around the world this week when it published a report that purportedly traced a series of cyberattacks on U.S. companies to a Shanghai-based unit of the Chinese army.

But some hackers have turned the tables on the cyber-expert by creating malicious versions of its 74-page report that were infected with computer viruses. They emailed the tainted reports to their victims this week in a bid to wreak havoc under Mandiant’s name.

Though the episode was embarrassing, the company said its systems were not breached. “Mandiant has not been compromised,” the company said on its corporate blog.

Mandiant was founded in 2004 by Kevin Mandia, a former U.S. Air Force cyber-forensics investigator who co-authored an influential textbook on the subject. The company made its name by automating processes used to investigate computer breaches.

Mandiant was largely unknown outside the computer security industry until Monday, when it fingered the People’s Liberation Army’s Shanghai-based Unit 61398 as the most likely driving force behind a Chinese hacking group known as APT1.

China’s Defense Ministry issued a flat denial of the accusations and called them “unprofessional.” But Mandiant won kudos for the unprecedented level of detail in its report, including the location of a building in Shanghai’s Pudong financial hub from which Mandiant said the unit had stolen “hundreds of terabytes of data from at least 141 organizations across a diverse set of industries beginning as early as 2006.”

Other security companies that have published reports on cyberattacks have shied away from so clearly identifying their perpetrators.

“It was a wonderful report,” said Michael Hayden, a former director of the CIA and National Security Agency, who is now with the Chertoff Group. “Everybody is saying ‘it’s about time.’”

The report did not identify the victims of APT1 or Mandiant’s customers, though the company says it has worked for about 40 percent of the Fortune 500.

When asked why he had decided to go public with this report, Mandia, 42, told Reuters, “There is mounting frustration in the private sector. Tolerance is shrinking. We also have a bunch of employees here who are ex-military who sense that frustration and said, ‘Let’s push this out.’”

The report comes ahead of next week’s annual RSA Conference on security in San Francisco, where Mandiant will showcase its products to help companies identify security breaches.

IPO IN THE CARDS?

Mandiant says it begins investigations by installing software it has developed that searches for infections by looking for evidence hackers leave behind. It refers to those digital signatures as Indicators of Compromise, or IOCs.

The proprietary database of those indicators makes up a critical part of the “special sauce” that automates the investigation process and, Mandiant says, enables investigators to root out attackers faster than rivals.

The company has thousands of IOCs in its database, which it is constantly expanding.

“We tend not to take the small jobs. We take the big ones – the ones you would love to read about in the paper, but we keep them out of the paper,” said Mandiant’s chief security officer, Richard Bejtlich.

Some investors have speculated that Mandiant is preparing for an initial public offering in the next year or so. On Friday, it named Mel Wesley to the post of chief financial officer. Wesley was CFO of publicly held OPNET, which was sold to Riverbed Technology in December for about $ 1 billion.

Mandia, who raised $ 70 million by selling stock to Silicon Valley venture capital firm Kleiner Perkins Caufield & Byers and One Equity Partners, the private investment arm of JPMorgan Chase & Co, said he is in no rush to go public. “I do not believe we need more capital,” he said.

Ted Schlein, a partner with Kleiner Perkins, declined to say if an IPO was in the works, but told Reuters: “They are certainly of the size and they certainly have the operating metrics to be a public company.”

Mandia said revenue soared 60 percent last year to about $ 100 million, and he expects it to climb at about the same clip this year on rising demand for Web-based services that help businesses identify when they have been attacked.

The New York Times and News Corp‘s Wall Street Journal recently disclosed that they hired Mandiant to investigate cyberattacks. The company has done similar work for Thomson Reuters Corp, parent of Reuters News, according to two sources with knowledge of the matter. A spokesman for Thomson Reuters declined to confirm it.

PREMIUM FEES

Mandiant declined to discuss its fees, though analysts say they are among the highest in an industry where rivals include much bigger companies such as Accenture, AT&T Inc, Deloitte, PwC and Verizon Communications Inc, which offer cyber-forensics alongside other services.

Mandiant consultants often bill at rates of $ 450 or more an hour, said a person familiar with the company. Teams of consultants investigate breaches for weeks and sometimes several months, typically ringing up bills of between $ 250,000 and $ 1 million.

John Pescatore, director of emerging security trends for the SANS Institute, says Mandiant can charge a premium partly because it gets strong recommendations from the government and other customers.

There is often a waiting list for its services.

“It’s supply and demand. You call Mandiant and Mandiant tells you when they can show up,” said the person familiar with the company, who was not authorized to publicly discuss its finances.

Mandiant also competes against CrowdStrike and Cylance, which are run by the founders of a company known as Foundstone, a pioneer in cyber-forensics that had hired Mandia away from the military. He left Foundstone in 2004 to start Mandiant.

(Reporting by Jim Finkle in Boston; Additional reporting by Joseph Menn in San Francisco and Deborah Charles in Washington; Editing by Tiffany Wu and Prudence Crowther)

Tech News Headlines – Yahoo! News

Title Post: Mandiant goes viral after China hacking report
Url Post: http://www.news.fluser.com/mandiant-goes-viral-after-china-hacking-report/
Link To Post : Mandiant goes viral after China hacking report
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Ian Ziering: Why My Pregnant Wife Pole Dances

Pregnancy does a body good. Then again, for Ian Ziering‘s expectant wife Erin, so does pole dancing.

The mom-to-be took up the sport following the birth of daughter Mia Loren, 22 months, when she found herself searching for a balance to all things baby.

“I think I got so wrapped up in the motherly world, I was looking for something to make me feel more womanly, more myself,” Erin tells The Bump.

After a night out with her friends, among them a pole dance instructor, the first-time mom — who was already pregnant with the couple’s second child — had her answer.

Courtesy Erin Ziering

“She was telling us that it will make you feel better about your body. It makes you feel more self-aware, and more confident, and that it helps with a lot of issues that happen after you have a baby,” Erin says, adding that while safe, she was still advised to check with her doctor first.

“It’s great exercise. I go once or twice a week, and it’s girl time with my friends. We go out to dinner afterwards,” she shares. “It’s been a great experience, and it kept me in great shape during my pregnancy with a lot of extra energy.”

But she’s not the only one seeing the results of her new talent; Former 90210 actor Ziering is also benefiting from the mama-to-be’s latest moves.

“I had some apprehension for Erin to be involved with that because, um, somehow in my past I’ve seen pole dancing, and I was concerned that a pregnant woman shouldn’t be doing those kinds of things,” he jokes.

Noting that her approach to the pole is “really from the workout perspective,” Ziering admits the pay off has been big in other areas as well. “It helps her get in touch with her sensuality, with her femininity, and with her sexuality, and this is great!” he explains.

“It helps her stay positive when she starts to feel [bad about her body]. Being like, ‘Yeah, I might be pregnant, but I’m making it look good!’ And on top of that, she just gets a little sexier! I think it’s great, and I’m really benefiting.”

With the couple’s second child due in May, Erin is ready for round two of baby bliss, determined to not let the anxiety of life with a newborn deter her from enjoying the experience.

“I felt like with Mia, I was always so nervous about everything, making sure I was doing everything perfectly and reading every book,” she says. “I think this time will be nice because I know what’s going on and I will be more relaxed.”

Ziering and Erin’s own childhoods allows the pair to be the perfect tag-team, although her medical background often tips the scale when it comes to making final decisions.

“We both benefit from growing up in very loving, nurturing environments. We come from similar upbringings,” he says. “Because Erin is a nurse, there’s a lot of credibility to her perspective of raising the baby that I really can’t argue with.”

He continues: “She’ll say, ‘I have looked into this,’ and explain it and I say, ‘Okay! You really have your finger on the heartbeat of child rearing,’ because she does. We go with it.”

Although he cherishes his recent role of a lifetime — dad! — fatherhood comes with its fair share of hardships. “I think the most challenging thing is keeping the stress level down during the times when the baby is inconsolable,” Ziering, 48, admits.

“But I understand that this is all a part of the work, and this is what I signed up for, and that it’s bond-building. I know that the view from the top is worth the climb.”

Joking that life with a toddler has left her less than prepared for the big arrival — “I could be pregnant longer, and it would be okay!” Erin says — she’s anticipating plenty of one-on-one time with baby after the birth.

“Mia will go to school for a couple of hours in the morning, and it will be a nice transition for her,” she explains. “She’ll be able to socialize, learn and be in a safe environment while I’m having bonding time with the new baby. We’re looking forward to that.”

Click here to read the full interview at The Bump.

– Anya Leon

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..